The lawsuits centered on deals known as “pay for delay,” in which a brand-name drugmaker pays or compensates a generic rival to delay releasing a cheaper version of its product. The deals are often made to resolve patent litigation.
Under the settlement, Teva will be prohibited from making these agreements with rivals. The FTC did not fine the generic drugmaker.
The FTC ruled that paying rivals not to enter the market is a violation of antitrust law.
“This broad settlement prevents the world’s largest manufacturer of generic drugs from entering into collusive agreements that prevent price competition by keeping generic drugs off the market,” FTC Chairman Joe Simons told Reuters.
Read the full report here.
More articles on pharmacy:
23andMe wants to become a drug company, has 13 drugs in its pipeline: 5 notes
J&J CEO on partnership with Apple: ‘We’re going to save lives’
Medicare would pay for CAR-T therapy under new proposal
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
